Characteristics | Anti-IFNg | Anti-TNFa | Placebo |
No. of patients | 20 | 20 | 15 |
Gender, M/F | 2/18 | 5/15 | 2/13 |
Age, years | 49.30 ± 11.45 | 50.85 ± 11.39 | 56.93 ± 9.30 |
Disease duration, years | 9.62 ± 7.49 | 14.3 ± 8.77 | 8.13 ± 8.76 |
Rheumatoid factor + | 17 | 15 | 13 |
Pain, VAS, cm | 6.15 ± 1.64 | 6.22 ± 1.47 | 6.89 ± 1.54 |
Morning stiffness, min. | 129.25 ± 111.05 | 101.00 ± 105.11 | 115.33 ± 107.42 |
Health physician status (1 - 5) patient | 3.55 ± 0.51 | 3.45 ± 0.51 | 3.46 ± 0.51 |
3.70 ± 0.57 | 3.5 ± 0.51 | 3.80 ± 0.67 | |
No. of swollen joints | 10.60 ± 5.49 | 10.0 ± 5.31 | 9.06 ± 2.98 |
No. of tender joints | 21.30 ± 8.35 | 20.20 ± 7.97 | 22.73 ± 5.52 |
Grip strength, right KPa left | 31.55 ± 20.71 | 37.70 ± 22.87 | 26.13 ± 11.519 |
27.45 ± 16.70 | 33.90 ± 29.53 | 19.06 ± 6.46 | |
Fatigue, VAS, cm | 6.35 ± 1.81 | 6.87 ± 1.83 | 6.97 ± 2.1 |
Hemoglobin, g/L | 113.44 ± 18.27 | 117.36 ± 18.92 | 113.5 ± 16.51 |
ESR, mm/hour | 35.83 ± 10.55 | 34.15 ± 10.92 | 43.00 ± 12.94 |
CRP, mg/dL | 2.3 ± 1.35 | 2.37 ± 2.54 | 2.5 ± 3.39 |
Patients on stable dose of prednisolone | 5 | 6 | 4 |
Number of previous DMARDs | 1.9 | 2.1 | 1.8 |